Option chain shows key data for Mainz Biomed's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Mainz Biomed.

Mainz Biomed (NASDAQ:MYNZ) Stock, Option Chain

Mainz Biomed

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Novavax,Vaccine,For,Prevention,Of,Coronavirus,,Covid-19,,Sars-cov-2,In,Doctors

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AFMD

BTOG

FBRX

GORV

HCTI

HKPD

LMFA

MOVE

MYNZ

NCNA

NVAX

PLRZ

PNBK

QSEA

SXTC

TOPW

TSSI

Why Novavax Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Screenshot 2025-04-15 at 7.03.21 PM

Biotech

Mainz Biomed Narrows Its Losses, Grows Revenue For Full Year 2024

Screenshot 2025-04-02 at 9.29.30 PM

General

Mainz BioMed&#39;s Trial To Bring Critical Early Cancer Detection One Step Closer

Mainz Biomed NV

Health Care

Press Releases

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Earnings

Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

Mainz Biomed Enters into Technology Partnership with EDX Medical Group

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Financing

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

180 Life Sciences

Azitra

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Galecto

Genprex

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Mustang Bio

Moleculin Biotech

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Polyrizon

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sunshine Biopharma

SILO Pharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Soligenix

Synaptogenix

Tharimmune

Xenetic Biosciences

Maxim Group

JonesTrading

Screenshot 2024-12-19 at 7.13.05 PM

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.

Screenshot 2024-11-21 at 6.41.48 PM

Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test

Screenshot 2024-11-12 at 8.43.58 PM

Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening

Screenshot 2024-11-11 at 7.48.49 PM

What Mainz Biomed (NASDAQ: MYNZ) Has Been Up To Recently And Why Frankie Muniz Is A Backer

Screenshot 2024-10-04 at 11.57.48 PM

Interview

Former Senior Advisor To Obama Joins Forces With Innovative Biotech To Catch Cancer Early

Screenshot 2024-09-04 at 5.52.15 PM

Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fight Pancreatic Cancer With Early Detection Tool

Screenshot 2024-08-30 at 2.55.26 PM

Emerging Markets

Early Cancer Detection Saves Lives - This Biotech Has A Promising New Test

Screenshot 2024-08-30 at 6.27.59 PM

EXAS

Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones

Comments

Mainz Biomed

Mainz Biomed (MYNZ) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell